欧洲诱导性多能干细胞 (iPSC) 市场，按细胞来源（皮肤细胞和血细胞）、类型（人类 IPSC 和小鼠 IPSC）、产品（仪器、消耗品和试剂盒及服务）、应用（学术研究、再生医学、细胞疗法、毒理学筛选、药物发现和开发、疾病建模、干细胞库、3D 生物打印等）、最终用户（生物技术和制药公司、研究实验室、诊断实验室等）、分销渠道（直接招标和零售销售）、国家（德国、英国、意大利、法国、西班牙、瑞士、俄罗斯、土耳其、比利时、荷兰和欧洲其他地区）划分 - 行业趋势与预测到 2029 年。
市场分析与洞察：欧洲诱导性多能干细胞 (iPSC) 市场
预计欧洲诱导多能干细胞 (iPSC) 市场将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场的复合年增长率为 8.9%，预计到 2029 年将达到 5.3579 亿美元。干细胞疗法研究活动的增加成为诱导多能干细胞 (iPSC) 市场增长的驱动力。
诱导性多能干细胞是一种源自成人体细胞组织的细胞，通过一组基因和因子重新编程，获得多能性。添加某些基因和因子以获得胚胎干细胞的明确特性。诱导性多能干细胞与细胞供体几乎相同，有助于疾病建模。逆转录病毒通常用作重新编程诱导性多能干细胞的载体。诱导性多能干细胞的主要应用是疾病建模、药物发现和开发、毒性研究和基因治疗。它们广泛用于治疗心血管疾病、糖尿病和各种癌症。人类诱导性多能干细胞表现出与疾病相关的特性，因为它携带疾病的特定基因型，从而能够以患者特定的方式提供新的治疗选择。
干细胞疗法的采用率不断提高、生物技术行业投资不断增加以及慢性病患病率不断上升，这些因素推动了诱导性多能干细胞 (iPSC) 市场的发展。预计推动欧洲诱导性多能干细胞 (iPSC) 市场增长的其他因素包括诱导性多能干细胞的广泛临床应用以及 iPSC 的新兴技术进步。
然而，干细胞疗法的高成本、肿瘤治疗替代品的可用性等因素阻碍了欧洲诱导性多能干细胞 (iPSC) 市场的增长。另一方面，产品线数量的增加、个性化医疗兴趣的增加以及医疗保健支出的激增为欧洲诱导性多能干细胞 (iPSC) 市场的增长提供了机会。严格的规则和法规以及 IPSC 的基因组不稳定性是欧洲诱导性多能干细胞 (iPSC) 市场面临的关键市场挑战。
诱导性多能干细胞 (iPSC) 市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和诱导性多能干细胞 (iPSC) 市场情景，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您创建收入影响解决方案以实现您的预期目标。
诱导性多能干细胞 (iPSC) 市场范围和市场规模
诱导多能干细胞 (iPSC) 市场根据细胞来源、类型、产品、应用、最终用户和分销渠道进行细分，各细分市场之间的增长可帮助您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
欧洲诱导多能干细胞 (iPSC) 市场根据细胞来源、类型、产品、应用、最终用户和分销渠道分为六个显著部分。
- 根据细胞来源，欧洲诱导性多能干细胞 (iPSC) 市场分为皮肤细胞和血细胞。2022 年，由于皮肤细胞来源广泛且知名度高，皮肤细胞细分市场预计将占据市场主导地位。
- 根据类型，欧洲诱导多能干细胞 (iPSC) 市场分为人类 IPSC 和小鼠 IPSC。由于法国老年人口不断增加和临床试验数量不断增加，预计 2022 年人类 IPSC 市场将占据主导地位。
- 根据产品，欧洲诱导多能干细胞 (iPSC) 市场细分为仪器、耗材和试剂盒以及服务。由于英国拥有发育和生殖生物学专家，研发投入不断增加，预计 2022 年耗材和试剂盒领域将占据市场主导地位。
- 根据应用，欧洲诱导多能干细胞 (iPSC) 市场细分为学术研究、再生医学、细胞治疗、毒理学筛选、药物发现和开发、疾病建模、干细胞库、3D 生物打印等。2022 年，药物发现和开发领域预计将占据市场主导地位，因为 iPSC 试验的外包最终促进了药物审批流程。
- 根据最终用户，欧洲诱导多能干细胞 (iPSC) 市场分为生物技术和制药公司、研究实验室、诊断实验室和其他。2022 年，生物技术和制药公司部门预计将占据市场主导地位，因为该地区最近已成为小型和大型生物制药公司的中心，并且已经变得依赖合同研究组织部门和其他临床服务进行研发运营。
- 根据分销渠道，欧洲诱导多能干细胞 (iPSC) 市场分为直接招标和零售。由于交付来源众多，预计 2022 年直接招标市场将占据主导地位。
诱导性多能干细胞 (iPSC) 市场国家级分析
对诱导多能干细胞 (iPSC) 市场进行了分析，并按上述国家、细胞来源、类型、产品、应用、最终用户和分销渠道提供了市场规模信息。
诱导多能干细胞 (iPSC) 市场报告涵盖的国家包括英国、德国、法国、西班牙、意大利、荷兰、瑞士、俄罗斯、土耳其、奥地利、爱尔兰和欧洲其他地区。
由于干细胞技术的使用不断增加，预计欧洲地区德国的人类 iPSC 领域将在 2022 年至 2029 年的预测期内以最高增长率增长。由于慢性病病例不断增加以及大量采用干细胞来源以获得更好的治疗，法国的人类 iPSC 领域在欧洲市场占据主导地位。英国引领市场增长，由于生物技术中心和研究活动数量的增加，人类 iPSC 领域在该国占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
主要市场参与者不断增加的战略活动提高了人们对诱导多能干细胞 (iPSC) 治疗的认识，从而推动了诱导多能干细胞 (iPSC) 市场的市场增长。
诱导性多能干细胞 (iPSC) 市场还为您提供每个国家特定市场增长的详细市场分析。此外，它还提供有关市场参与者战略及其地理分布的详细信息。数据适用于 2011 年至 2020 年的历史时期。
竞争格局和诱导性多能干细胞 (iPSC) 市场份额分析
诱导性多能干细胞 (iPSC) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对诱导性多能干细胞 (iPSC) 市场的关注有关。
从事诱导性多能干细胞 (iPSC) 业务的主要公司包括 Thermo Fisher Scientific Inc.、FUJIFILM Corporation、LumaCyte、Horizon Discovery Ltd.、Takara Bio Inc.、Lonza.、Evotec SE.、Axol Bioscience Ltd.、R & D Systems, Inc.、Charles River Laboratories International, Inc.、Corning Incorporated、REPROCELL Inc.、Merck KGaA 以及其他国内公司。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。
全球各地的公司也签订了许多合同和协议，这也加速了诱导多能干细胞 (iPSC) 市场的发展。
例如，
- 2021 年 2 月，赛默飞世尔科技公司宣布其在年度 CMO 领导力奖中获得六个奖项。该奖项由 Life Science Leader 和 Outsourced Pharma 颁发，旨在表彰生物制药和生物技术公司评选出的顶级合同制造合作伙伴。据估计，这一认可有望加强公司在欧洲市场的影响力，并在未来几年推动公司的增长。
- 2020 年 6 月，LumaCyte 与 Catalent 合作，后者是欧洲领先的药物、生物制剂、细胞和基因疗法以及消费者健康产品交付技术、开发和制造解决方案提供商。此次合作有助于扩大该公司的干细胞技术产品 Radiance 及其应用。
市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在兽医输液泵市场的影响力，这也为组织的利润增长带来了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CELL SOURCE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 EUROPE MEDICAL CARTS MARKET: REGULATIONS
5.1 REGULATION IN U.S.
5.2 REGULATION IN CANADA
5.3 REGULATION IN EUROPE
5.4 REGULATION IN INDIA
5.5 REGUALTION IN JAPAN
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS
6.1.2 EMERGING TECHNOLOGICAL ADVANTAGES OF IPSCS
6.1.3 RISING PREVALENCE OF SEVERAL CHRONIC DISEASES
6.1.4 INCREASING ADOPTION OF STEM CELL THERAPY
6.1.5 GROWING BIOTECHNOLOGY SECTOR WITH BETTER INVESTMENT
6.2 RESTRAINT
6.2.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES AND LARGE-SCALE APPLICATIONS OF IPSCS
6.2.2 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT
6.2.3 ADVERSE EFFECTS OF STEM CELL TRANSPLANTS
6.3 OPPORTUNITIES
6.3.1 INCREASING NUMBER OF PIPELINE PRODUCTS
6.3.2 INCREASING INTEREST OF PERSONALIZED MEDICINE
6.3.3 SURGE IN HEALTHCARE EXPENDITURE
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 GENOMIC INSTABILITY OF IPSCS IS THE KEY MARKET CHALLENGE
6.4.2 LACK OF SKILLED PROFESSIONALS
6.4.3 STRINGENT REGULATORY FRAMEWORK
7 IMPACT OF COVID-19 ON THE EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS BY MANUFACTURERS
7.5 CONCLUSION
8 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE
8.1 OVERVIEW
8.2 SKIN CELLS
8.2.1 FIBROBLAST
8.2.2 KERATINOCYTES
8.2.3 ADIPOSE DERIVED STEM CELLS
8.2.4 HEPATOCYTES
8.2.5 MELANOCYTES
8.2.6 NEURAL STEM CELLS
8.2.7 OTHERS
8.3 BLOOD CELLS
8.3.1 PERIPHERAL BLOOD
8.3.2 CORD BLOOD ENDOTHELIAL CELLS
8.3.3 CORD BLOOD STEM CELLS
8.3.4 OTHERS
9 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE
9.1 OVERVIEW
9.2 HUMAN IPSCS
9.3 MOUSE IPSCS
10 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT
10.1 OVERVIEW
10.2 CONSUMABLES & KITS
10.2.1 REPROGRAMMING KITS
10.2.2 MEDIA
10.2.3 TRANSFECTION KITS
10.2.4 CELL IDENTIFICATION KITS
10.2.5 ACCESSORIES
10.2.6 OTHERS
10.3 SERVICES
10.4 INSTRUMENTS
10.4.1 IMAGING SYSTEMS
10.4.2 ELECTROPORATION DEVICE
10.4.3 INCUBATORS
10.4.4 OTHERS
11 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 DRUG DISCOVERY AND DEVELOPMENT
11.3 ACADEMIC RESEARCH
11.4 DISEASE MODELLING
11.5 CELLULAR THERAPY
11.6 REGENERATIVE MEDICINE
11.7 TOXICOLOGY SCREENING
11.8 STEM CELL BANKING
11.9 3D BIOPRINTING
11.1 OTHERS
12 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER
12.1 OVERVIEW
12.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
12.3 RESEARCH LABORATORIES
12.4 DIAGNOSTIC LABORATORIES
12.5 OTHERS
13 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 FRANCE
14.1.3 U.K.
14.1.4 ITALY
14.1.5 RUSSIA
14.1.6 SPAIN
14.1.7 TURKEY
14.1.8 NETHERLANDS
14.1.9 SWITZERLAND
14.1.10 BELGIUM
14.1.11 REST OF EUROPE
15 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 FUJIFILM CORPORATION
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.1.5.1 ACQUISITION
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.2.5.1 EVENT
17.2.5.2 ACQUISITION
17.3 LONZA.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.3.5.1 EXPANSION
17.4 MERCK KGAA
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.4.5.1 AGREEMENT
17.5 EVOTEC SE.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.5.5.1 AGREEMENT
17.5.5.2 COLLABORATION
17.6 APPLIED STEMCELL.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.6.3.1 PRODUCT LAUNCH
17.7 AXOL BIOSCIENCE LTD.
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.7.3.1 MERGER
17.7.3.2 PRODUCT LAUNCH
17.8 CELL APPLICATIONS, INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.8.3.1 PARTNERSHIP
17.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENT
17.9.4.1 ACQUISITION
17.1 CITIUS PHARMACEUTICALS, INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.10.3.1 AGREEMENT
17.11 CORNING INCORPORATED
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.11.4.1 AGREEMENT
17.12 FATE THERAPEUTICS
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.12.3.1 CLINICAL TRIAL
17.13 GENECOPOEIA, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 HOPSTEM BIOTECHNOLOGY LLC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.14.3.1 PARTNERSHIP
17.15 HORIZON DISCOVERY LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 LUMACYTE
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.16.3.1 COLLABORATION
17.17 R & D SYSTEMS, INC.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 REPROCELL INC.
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENTS
17.18.3.1 COLLABORATION
17.18.3.2 FACILITY EXPANSION
17.18.3.3 SERVICE LAUNCH
17.19 TAKARA BIO INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.19.4.1 NEW FACILITY LAUNCH
17.2 UNIVERSAL CELLS INC. (AN ASTELLAS COMPANY)
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.20.4.1 ACQUISITION
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.
TABLE 2 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 3 EUROPE SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 5 EUROPE BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 EUROPE HUMAN IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE MOUSE IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 11 EUROPE CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 13 EUROPE SERVICES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 16 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE DRUG DISCOVERY AND DEVELOPMENT IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE ACADEMIC RESEARCH IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE DISEASE MODELLING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE CELLULAR THERAPY IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE REGENERATIVE MEDICINE IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE TOXICOLOGY SCREENING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE STEM CELL BANKING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE 3D BIOPRINTING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 27 EUROPE BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE RESEARCH LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE DIAGNOSTIC LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 EUROPE DIRECT TENDER IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE RETAIL SALES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 35 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 36 EUROPE SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 37 EUROPE BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 38 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 40 EUROPE INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 41 EUROPE CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 42 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 46 GERMANY SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 47 GERMANY BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 48 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 50 GERMANY INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 51 GERMANY CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 52 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 53 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 56 FRANCE SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 57 FRANCE BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 58 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 60 FRANCE INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 61 FRANCE CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 62 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 63 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 66 U.K. SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 67 U.K. BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 68 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 70 U.K. INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 71 U.K. CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 72 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 75 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 76 ITALY SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 77 ITALY BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 78 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 80 ITALY INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 81 ITALY CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 82 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 83 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 86 RUSSIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 87 RUSSIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 88 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 90 RUSSIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 91 RUSSIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 92 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 93 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 96 SPAIN SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 97 SPAIN BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 98 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 100 SPAIN INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 101 SPAIN CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 102 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 103 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 104 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 105 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 106 TURKEY SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 107 TURKEY BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 108 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 110 TURKEY INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 111 TURKEY CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 112 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 113 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 114 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 115 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 116 NETHERLANDS SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 117 NETHERLANDS BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 118 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 120 NETHERLANDS INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 121 NETHERLANDS CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 122 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 123 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 124 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 125 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 126 SWITZERLAND SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 127 SWITZERLAND BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 128 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 130 SWITZERLAND INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 131 SWITZERLAND CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 132 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 133 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 134 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 135 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 136 BELGIUM SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 137 BELGIUM BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 138 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 140 BELGIUM INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 141 BELGIUM CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 142 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 143 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 144 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 145 REST OF EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION
FIGURE 2 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION
FIGURE 11 THE WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS (IPSC) ARE EXPECTED TO DRIVE THE EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SKIN CELLS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
FIGURE 15 PREVALENCE OF CHRONIC DISEASES
FIGURE 16 NUMBER OF PEOPLE WITH DIABETES (MILLION) AMONG AGES 20–79 YEARS
FIGURE 17 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2021
FIGURE 18 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2020-2029 (USD MILLION)
FIGURE 19 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, CAGR (2022-2029)
FIGURE 20 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, LIFELINE CURVE
FIGURE 21 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, 2021
FIGURE 22 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 23 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 24 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, 2021
FIGURE 26 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 27 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 28 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 29 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2021
FIGURE 30 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 31 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 32 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 33 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, 2021
FIGURE 34 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 35 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 36 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 38 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 39 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 40 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SNAPSHOT (2021)
FIGURE 42 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021)
FIGURE 43 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 44 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 45 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE (2022-2029)
FIGURE 46 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
